

Corrado Campochiaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/864212/publications.pdf>

Version: 2024-02-01

177
papers

5,935
citations

126907

33
h-index

88630

70
g-index

179
all docs

179
docs citations

179
times ranked

9136
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e325-e331.	3.9	808
2	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	2.2	349
3	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19.	5.6	292
4	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021, 27, 451-457.	6.0	243
5	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.9	212
6	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine, the</i> , 2021, 9, 522-532.	10.7	195
7	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e465-e473.	3.9	173
8	The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1691-1695.	0.9	163
9	Ventricular Arrhythmias in Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1046-1057.	2.8	148
10	Arrhythmias in myocarditis: State of the art. <i>Heart Rhythm</i> , 2019, 16, 793-801.	0.7	142
11	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e253-e261.	3.9	140
12	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 223-229.	2.2	123
13	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2016, 55, 883-890.	1.9	121
14	IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 135-145.	1.1	106
15	An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. <i>Arthritis Care and Research</i> , 2018, 70, 1671-1678.	3.4	103
16	BRAF ^{V600E} -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602.	0.9	94
17	Ankylosing Spondylitis and Axial Spondyloarthritis. <i>New England Journal of Medicine</i> , 2016, 375, 1302-1303.	27.0	83
18	Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 48-54.	3.4	75

#	ARTICLE	IF	CITATIONS
19	Antineutrophil cytoplasmic antibody positivity in IgG4-related disease. <i>Medicine (United States)</i> , 2016, 95, e4633.	1.0	69
20	Efficacy and safety of biological agents in adult-onset Still's disease. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 309-314.	1.1	66
21	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> , 2017, 56, 2084-2092.	1.9	60
22	Methotrexate for maintenance of remission in IgG4-related disease: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1934-1936.	1.9	54
23	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 1335.	4.8	53
24	Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. <i>Blood Purification</i> , 2021, 50, 102-109.	1.8	53
25	Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. <i>European Journal of Internal Medicine</i> , 2020, 74, 92-98.	2.2	52
26	Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1252-1253.	0.9	51
27	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	2.5	49
28	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. <i>Rheumatology</i> , 2020, 59, 2435-2442.	1.9	46
29	Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. <i>Autoimmunity Reviews</i> , 2015, 14, 352-357.	5.8	44
30	Low prevalence of arrhythmias in clinically stable COVID-19 patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 891-893.	1.2	43
31	An update on targeted therapies in systemic sclerosis based on a systematic review from the last 30 years. <i>Arthritis Research and Therapy</i> , 2021, 23, 155.	3.5	42
32	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
33	Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1644-1656.	2.8	39
34	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233.	4.8	37
35	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018, 57, e11-e12.	2.2	36
36	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 675678.	4.8	35

#	ARTICLE	IF	CITATIONS
37	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. <i>Rheumatology</i> , 2020, 59, 2523-2533.	1.9	35
38	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018, 169, 819.	3.9	34
39	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
40	Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. <i>International Journal of Cardiology</i> , 2019, 280, 110-116.	1.7	33
41	Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1221-1234.	3.2	32
42	Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave. <i>European Journal of Internal Medicine</i> , 2021, 88, 144-146.	2.2	32
43	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.9	32
44	Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152017.	3.4	32
45	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 54.	3.5	31
46	Guidelines for the use and interpretation of diagnostic methods in adult food allergy. <i>Clinical and Molecular Allergy</i> , 2015, 13, 27.	1.8	30
47	Intrathecal rituximab for IgG ₄ -related hypertrophic pachymeningitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 441-444.	1.9	30
48	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , 2020, 77, 9-17.	2.2	30
49	Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 816-817.	0.9	30
50	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , 2017, 6, e1318237.	4.6	29
51	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	3.5	29
52	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.8	29
53	Deconstructing IgG4-related disease involvement of midline structures: Comparison to common mimickers. <i>Modern Rheumatology</i> , 2017, 27, 638-645.	1.8	28
54	The conundrum of interleukin-6 blockade in COVID-19. <i>Lancet Rheumatology</i> , The, 2020, 2, e579-e580.	3.9	28

#	ARTICLE	IF	CITATIONS
55	CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade. <i>Arthritis and Rheumatology</i> , 2020, 72, 565-575.	5.6	27
56	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
57	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	4.8	26
58	“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	1.6	25
59	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	3.9	25
60	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	3.4	24
61	Efficacy and safety of apremilast for Behçet’s syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020, 59, 171-175.	1.9	23
62	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 482-490.	1.1	22
63	Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 288-292.	5.3	22
64	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	1.9	21
65	Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1584-1593.	0.9	21
66	Successful use of cyclosporin A and interleukin-1 blocker combination therapy in <scp>VEXAS</scp> syndrome: a single-center case series. <i>Arthritis and Rheumatology</i> , 2022, 74, 1302-1303.	5.6	21
67	Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. <i>Journal of Autoimmunity</i> , 2020, 106, 102330.	6.5	20
68	A radiological predictor for pneumomediastinum/pneumothorax in COVID-19 ARDS patients. <i>Journal of Critical Care</i> , 2021, 66, 14-19.	2.2	19
69	Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. <i>Rheumatology</i> , 2021, 60, 465-467.	1.9	18
70	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. <i>European Journal of Internal Medicine</i> , 2021, 84, 63-67.	2.2	18
71	Telemedicine in myocarditis: Evolution of a multidisciplinary “disease unit” at the time of COVID-19 pandemic. <i>American Heart Journal</i> , 2020, 229, 121-126.	2.7	17
72	COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 58-65.	1.7	17

#	ARTICLE	IF	CITATIONS
73	The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 1974.	2.4	16
74	Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1771-1780.	5.3	16
75	Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1549-1558.	2.4	15
76	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.9	15
77	Drug induced exfoliative dermatitis: state of the art. <i>Clinical and Molecular Allergy</i> , 2016, 14, 9.	1.8	14
78	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncology</i> , 2016, 5, e1181244.	4.6	14
79	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. <i>Arthritis Research and Therapy</i> , 2017, 19, 156.	3.5	14
80	Patient-reported outcome instruments in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 90-102.	1.7	14
81	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	3.4	14
82	Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. <i>Annals of Intensive Care</i> , 2021, 11, 152.	4.6	14
83	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e143-e146.	0.9	13
84	Bortezomib in Type I Cryoglobulinemic Vasculitis: Are We Acting Too Late?. <i>Internal Medicine</i> , 2015, 54, 1119-1123.	0.7	12
85	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
86	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
87	Nasal Mucosa Narrow Band Imaging in Granulomatosis with Polyangiitis (Wegener Granulomatosis): A Preliminary Study. <i>American Journal of Rhinology and Allergy</i> , 2015, 29, 170-174.	2.0	11
88	Juxta-vertebral lesions in granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 356-360.	3.4	11
89	Diagnosing Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e19-e19.	0.9	10
90	Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e113-e113.	0.9	10

#	ARTICLE	IF	CITATIONS
91	Response to: "More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia" by Ferraccioli. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e158-e158.	0.9	10
92	High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 849-854.	1.9	10
93	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	1.4	10
94	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , 2021, 8, 723506.	2.6	10
95	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	1.9	10
96	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020, 47, 1780-1784.	2.0	9
97	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	5.8	9
98	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 129-134.	0.8	9
99	Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis. <i>Clinical Immunology</i> , 2019, 199, 18-24.	3.2	8
100	Response to: "Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey" by Comarmond et al". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e31-e31.	0.9	8
101	PET in Takayasu arteritis: onwards and upwards towards a future of robust multimodality disease activity assessment?. <i>Rheumatology</i> , 2022, 61, S14-S15.	1.9	8
102	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1139-1145.	3.4	8
103	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.8	8
104	Serum CXCL12 levels on hospital admission predict mortality in patients with severe sepsis/septic shock. <i>American Journal of Emergency Medicine</i> , 2015, 33, 1802-1804.	1.6	7
105	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.9	7
106	Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency. <i>BMJ Case Reports</i> , 2019, 12, e223180.	0.5	7
107	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6.	2.2	7
108	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , 2021, 11, 2165.	2.6	7

#	ARTICLE	IF	CITATIONS
109	Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort. <i>Modern Rheumatology</i> , 2022, 32, 406-412.	1.8	7
110	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	2.2	7
111	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
112	Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. <i>Lancet Rheumatology</i> , The, 2022, 4, e507-e516.	3.9	7
113	BRAF Mutations in Erdheim-Chester Disease. <i>Dermatologic Clinics</i> , 2016, 34, xi-xii.	1.7	6
114	Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 509-510.	1.1	6
115	Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 166-167.	1.1	6
116	<p>Multimodal Chorioretinal Imaging in Erdheim-Chester Disease</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 581-588.	1.8	6
117	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1498-1501.	0.9	6
118	Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 9-18.	0.5	6
119	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
120	Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. <i>European Journal of Internal Medicine</i> , 2022, 103, 95-99.	2.2	6
121	Allopurinol-induced severe cutaneous adverse reactions. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e20-e20.	0.9	5
122	Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. <i>Modern Rheumatology</i> , 2016, 26, 276-277.	1.8	5
123	Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. <i>Minerva Anestesiologica</i> , 2021, 87, 891-902.	1.0	5
124	Development of systemic sclerosis in transgender females: a case series and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 50-52.	0.8	5
125	A case of granulomatosis with polyangiitis: rheumatoid arthritis overlap syndrome presenting as cervical cancer successfully treated with rituximab. <i>Internal Medicine Journal</i> , 2016, 46, 745-746.	0.8	4
126	Autoantibodies in autoimmune rheumatic disease. <i>Medicine</i> , 2018, 46, 78-83.	0.4	4

#	ARTICLE	IF	CITATIONS
127	Mavrilimumab for severe COVID-19 – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e662-e663.	3.9	4
128	Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 183-186.	1.1	4
129	Painful fingers. <i>European Journal of Internal Medicine</i> , 2013, 24, e63-e64.	2.2	3
130	Letter by Campochiaro et al Regarding Article, “Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity”. <i>Circulation</i> , 2018, 137, 2421-2422.	1.6	3
131	Spontaneous Coronary-Artery Dissection. <i>New England Journal of Medicine</i> , 2021, 384, 1077-1078.	27.0	3
132	Serum KL-6 as a marker of disease progression in SSc-ILD. , 2018, , .		3
133	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 25-28.	0.8	3
134	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 179-188.	1.7	3
135	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2018, 25, 1.	0.9	2
136	AB0621 – GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
137	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	6.5	2
138	Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it?. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 2189-2190.	0.7	2
139	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. <i>Journal of Rheumatology</i> , 2019, 46, 1421-1422.	2.0	1
140	E074 – Developing a molecular classifier for scleroderma spectrum disorders to augment clinical categorisation. <i>Rheumatology</i> , 2019, 58, .	1.9	1
141	Bilateral temporal arteries 18F-FDG PET uptake in giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 343-343.	1.9	1
142	Clinically isolated aortitis successfully treated with methotrexate monotherapy. <i>Rheumatology</i> , 2020, 59, e54-e56.	1.9	1
143	Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 77-86.	0.8	1
144	Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement. <i>International Journal of Dermatology</i> , 2021, 60, e359-e361.	1.0	1

#	ARTICLE	IF	CITATIONS
145	P154 High-density proteomic analysis of skin blister fluid and plasma in systemic sclerosis identifies local and systemic differences for key proteins. <i>Rheumatology</i> , 2021, 60, .	1.9	1
146	Cardiac immune-related adverse events: an immune-cardio-oncology puzzle. <i>European Journal of Heart Failure</i> , 2021, 23, 1748-1749.	7.1	1
147	In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. <i>Rheumatology</i> , 2021, 60, 5493-5494.	1.9	1
148	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 129-134.	0.8	1
149	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
150	Lights and shadows on JAK inhibitors for Ankylosing Spondylitis. <i>European Journal of Internal Medicine</i> , 2022, 102, 43-44.	2.2	1
151	199 Frequency and clinical association of rare antibodies in a large connective tissue disease cohort. <i>Rheumatology</i> , 2018, 57, .	1.9	0
152	206 Proton pump inhibitor use is associated with calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 57, .	1.9	0
153	205 Serum tryptophan and kynurenine levels are altered in systemic sclerosis patients and show distinct clinical and autoantibody associations suggesting potential role in pathogenesis. <i>Rheumatology</i> , 2018, 57, .	1.9	0
154	357 EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
155	168 GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU'S ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
156	273 TAKAYASU'S ARTERITIS: BEYOND THE VESSELS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
157	288 DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN EIGHT BIOLOGICS IN PATIENTS WITH TAKAYASU'S ARTERITIS: A SINGLE-CENTER EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
158	Diagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment on Antisynthetase syndrome and cardiac involvement: a rare association by Meudec et al. <i>Joint Bone Spine</i> 2018. doi: 10.1016/j.jbspin.2018.09.019. <i>Joint Bone Spine</i> , 2019, 86, 407.	1.6	0
159	FRI0585 EFFICACY OF CANAKINUMAB AS FIRST-LINE BIOLOGIC AGENT IN ADULT-ONSET STILL'S DISEASE. , 2019, , .		0
160	AB0613 PRESENTATION OF TAKAYASU ARTERITIS ACCORDING TO THE AGE OF ONSET IN A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
161	AB0620 EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. , 2019, , .		0
162	THU0570 EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
163	THU0293â€¦DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN SEVEN BIOLOGICS IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS: A SINGLE-CENTER EXPERIENCE. , 2019, , .		0
164	FRI0584â€¦EFFICACY AND SAFETY OF RITUXIMAB FOR INDUCTION OF REMISSION AND MAINTENANCE OF IGG4-RELATED DISEASE: EXPERIENCE FROM AN ITALIAN NATIONAL REFERRAL CENTRE. , 2019, , .		0
165	FRI0587â€¦IGG4-RELATED DISEASE IN ITALY: RESULTS FROM A MONOCENTRIC COHORT OF 150 PATIENTS (2013â€“2018). , 2019, , .		0
166	FRI0302â€¦SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY. , 2019, , .		0
167	THU0319â€¦TAKAYASUâ€™S ARTERITIS: BEYOND THE VESSELS. , 2019, , .		0
168	P154â€¦Stage and subset specific profiles of fibrogenesis highlighted through analysis of serum markers across the scleroderma spectrum. Rheumatology, 2020, 59, .	1.9	0
169	P155â€¦Co-existence of scleroderma hallmark autoantibodies associates with distinct clinical phenotype. Rheumatology, 2020, 59, .	1.9	0
170	Efficacy and Safety of IL-6 Inhibitors in Patients with COVID-19 Pneumonia: A Systematic Review and Meta-Analysis of Multicentre, Randomised Trials. SSRN Electronic Journal, 0, , .	0.4	0
171	The choice of early treatment and the impact of future relapses in adult onset Stillâ€™s disease. Rheumatology, 2021, 60, 2500-2501.	1.9	0
172	O18â€¦Integrated molecular analysis of systemic sclerosis skin and blood shows significant differences between major autoantibody subgroups. Rheumatology, 2021, 60, .	1.9	0
173	Myocardial infarction in giant cell arteritis: It is all a matter of balance.. European Journal of Internal Medicine, 2021, 89, 1-2.	2.2	0
174	Response to â€œCorrespondence on â€œImpact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric surveyâ€™â€™ by Montero et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220959.	0.9	0
175	Lung involvement in systemic sclerosis. Handbook of Systemic Autoimmune Diseases, 2022, , 73-103.	0.1	0
176	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
177	P229â€¦Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis. Rheumatology, 2022, 61, .	1.9	0